Decreased risk of renal cell carcinoma in patients with type 2 diabetes treated with sodium glucose cotransporter‐2 inhibitors

• Published in: Cancer science Vol. 115; no. 6; pp. 2059 - 2066
• Main Authors: Chiu, Chun‐Huei, Wang, Wei‐Yao, Chen, Hung‐Yi, Liao, Pei‐Lun, Jong, Gwo‐Ping, Yang, Tsung‐Yuan
• Format: Journal Article
• Language: English
• Published: England John Wiley & Sons, Inc 01.06.2024; John Wiley and Sons Inc
• Subjects: Adult; Age; Aged; Carcinoma, Renal Cell - drug therapy; Carcinoma, Renal Cell - epidemiology; Cardiovascular disease; Cell cycle; chronic kidney disease; Chronic obstructive pulmonary disease; Codes; Comorbidity; Diabetes; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Epidemiology; Female; Glucose; Humans; Hypertension; Incidence; Kidney cancer; Kidney diseases; Kidney Neoplasms - drug therapy; Male; Middle Aged; Nonsteroidal anti-inflammatory drugs; Original; ORIGINAL ARTICLES; Patients; Population studies; Prescriptions; Proportional Hazards Models; Renal cell carcinoma; Retrospective Studies; Rheumatoid arthritis; Risk Factors; Sensitivity analysis; SGLT2 inhibitor; Sodium; Sodium-Glucose Transporter 2 Inhibitors - adverse effects; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use; type 2 DM; chronic kidney disease; renal cell carcinoma; comorbidity; type 2 DM; SGLT2 inhibitor

Patients with type 2 diabetes (T2D) are at a higher risk of developing renal cell carcinoma (RCC) than the general population. In vitro and in vivo investigations of the effects of sodium glucose cotransporter‐2 inhibitors (SGLT2I) have shown a significantly reduced risk of RCC. However, the impact...